Residency · Residency · Dermatology

Morbilliform Drug Eruptions and the DRESS Syndrome

Introduction

Drug eruptions are among the most common reasons for inpatient dermatology consultation. Morbilliform (exanthematous) drug eruptions represent the most frequent cutaneous adverse drug reaction, while Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome represents a severe, potentially life-threatening systemic hypersensitivity reaction. Distinguishing between these entities and recognizing the features that mandate urgent intervention are essential clinical skills.

Morbilliform Drug Eruptions

Epidemiology and Pathogenesis

Morbilliform drug eruptions account for 75 to 95% of all cutaneous drug reactions, with an incidence of 1 to 5% of first-time drug exposures that is higher with certain drugs (aminopenicillins 5 to 10%, sulfonamides 3 to 6%). They represent a type IVb delayed hypersensitivity reaction mediated by drug-specific CD4+ T cells releasing Th2 cytokines (IL-4, IL-5, IL-13). The typical onset is 5 to 14 days after initiation of the culprit drug with first exposure, though onset can occur within 1 to 2 days on re-exposure.

Common Culprit Drugs

The most common culprit drugs include antibiotics (aminopenicillins such as amoxicillin, sulfonamides such as TMP-SMX, cephalosporins, and quinolones), anticonvulsants (phenytoin, carbamazepine, lamotrigine, which can also cause DRESS and SJS, making clinical distinction critical), allopurinol, NSAIDs, and antineoplastic agents. A notable clinical scenario is the amoxicillin-EBV interaction: 70 to 100% of patients with acute EBV mononucleosis develop a morbilliform eruption when given aminopenicillins. This is not a true drug allergy and does not contraindicate future penicillin use.

Clinical Features

The eruption consists of symmetrically distributed, erythematous macules and papules that often coalesce into patches, beginning on the trunk and spreading to the extremities. Pruritus is common. The face, palms, and soles may be involved but are not the predominant sites. Mucous membranes are spared, and there are no systemic symptoms (no fever, no organ involvement), which is what distinguishes a simple morbilliform eruption from DRESS. The eruption may progress despite drug discontinuation before resolving over 1 to 2 weeks, and fine desquamation may occur during resolution.

Diagnosis

The diagnosis is clinical, based on temporal correlation with drug exposure and characteristic morphology. No specific laboratory test exists; eosinophilia is mild or absent (unlike DRESS). Skin biopsy, if needed, shows interface dermatitis with eosinophils in the superficial dermis, and necrotic keratinocytes may be present but are sparse. Drug provocation testing and patch testing may help identify the culprit drug retrospectively but are not routinely performed acutely.

Management

The suspected drug should be discontinued when possible and alternatives identified. Symptomatic treatment with medium-potency topical corticosteroids and oral antihistamines for pruritus is usually sufficient. The eruption is self-limited, resolving within 1 to 2 weeks after drug cessation. The reaction should be documented in the medical record, and the patient counseled to avoid the culprit drug in the future. In some clinical scenarios, "treating through" the eruption while continuing the drug is acceptable (for example, a morbilliform eruption to amoxicillin in a patient without EBV), with close monitoring for progression to DRESS or SJS.

Red Flags Suggesting Progression Beyond Simple Morbilliform Eruption

Several features should raise concern for DRESS, SJS/TEN, or other severe drug reactions: facial edema, fever above 38.5 C, mucous membrane involvement, skin pain or tenderness rather than itch, targetoid lesions, vesicles, or bullae, lymphadenopathy, and laboratory abnormalities (eosinophilia, atypical lymphocytes, elevated transaminases). Any of these findings warrants immediate reassessment.

<image>Clinical photographs comparing a simple morbilliform drug eruption showing symmetric erythematous macules and papules on the trunk without mucosal involvement versus early DRESS syndrome showing facial edema, confluent erythema, and periorbital swelling</image>

DRESS Syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms)

Overview

Also known as Drug-Induced Hypersensitivity Syndrome (DIHS), DRESS is a severe, potentially fatal systemic hypersensitivity reaction with a mortality rate of 5 to 10%. It is characterized by the triad of a cutaneous eruption, hematologic abnormalities (eosinophilia and/or atypical lymphocytosis), and internal organ involvement. DRESS is distinguished by a longer latency period (2 to 8 weeks) than simple morbilliform eruptions and a prolonged, relapsing course.

Pathogenesis

The pathogenesis involves a complex interplay of drug-specific T-cell activation, HHV-6 reactivation, and regulatory T-cell deficiency. The drug or its reactive metabolites activate CD4+ and CD8+ T cells. HHV-6 reactivation occurs in 40 to 60% of DRESS cases and correlates with more severe organ involvement, representing a defining feature of the DIHS concept. Other herpesvirus reactivations (HHV-7, EBV, CMV) may also occur sequentially. Oligoclonal T-cell expansion targets both drug antigens and viral antigens through molecular mimicry. Genetic susceptibility involves strong HLA associations with specific drug-HLA pairings: carbamazepine with HLA-A31:01 (European) and HLA-B15:02 (associated more with SJS in Southeast Asian populations), allopurinol with HLA-B58:01, dapsone with HLA-B13:01, and abacavir with HLA-B*57:01 (hypersensitivity, not classic DRESS).

Common Culprit Drugs

The classic culprits are the aromatic anticonvulsants: carbamazepine, phenytoin, lamotrigine, and phenobarbital, with 40 to 58% cross-reactivity between these agents. Allopurinol is the most common non-anticonvulsant cause. Other culprits include sulfonamides (especially dapsone), vancomycin, minocycline, and abacavir.

Clinical Features

The latency is 2 to 8 weeks after drug initiation, longer than other drug reactions. The cutaneous eruption is a widespread morbilliform eruption that may become infiltrated, edematous, or purpuric, and facial edema (especially periorbital) is highly characteristic. Fever is typically high (above 38.5 C) and is often the initial symptom. Lymphadenopathy is generalized in 50 to 70% of cases. Hematologic abnormalities include eosinophilia (above 1500/microL in 60 to 90%), atypical lymphocytosis (resembling mononucleosis), and leukocytosis.

Organ involvement occurs in order of frequency. The liver (60 to 80%) is most commonly affected, with hepatitis ranging from mild transaminase elevation to fulminant hepatic failure, the leading cause of DRESS mortality. The kidney (10 to 30%) may show interstitial nephritis, proteinuria, and elevated creatinine. The lung (5 to 25%) can develop interstitial pneumonitis or pleural effusion. The heart (2 to 10%) may develop myocarditis or pericarditis, which can present weeks after cutaneous resolution. The thyroid frequently develops autoimmune thyroiditis as a delayed sequela months after DRESS resolution. Pancreatic and CNS involvement are less common but reported.

Diagnostic Criteria (RegiSCAR Scoring System)

The RegiSCAR scoring system evaluates fever above 38.5 C, enlarged lymph nodes (at least 2 sites, greater than 1 cm), eosinophilia (above 700/microL or above 10% if leukopenia), atypical lymphocytes, skin involvement (above 50% BSA), organ involvement (at least 1 organ), resolution longer than 15 days, and a negative workup for other causes (ANA, blood cultures, hepatitis serology). Score categories are: no case (below 2), possible (2 to 3), probable (4 to 5), and definite (above 5).

Management

Acute Management

Immediate discontinuation of the culprit drug is the single most important intervention. Systemic corticosteroids (prednisone 0.5 to 1 mg/kg/day) are used for moderate-to-severe DRESS with a prolonged taper over 8 to 12 weeks minimum, as rapid taper frequently causes relapse. Monitoring for rebound flare and herpesvirus reactivation (checking HHV-6 PCR) is essential. Cyclosporine (3 to 5 mg/kg/day) is increasingly used for steroid-refractory DRESS or as a steroid-sparing agent. Supportive care includes IV fluids, nutritional support, and wound care for skin.

Monitoring

During the acute phase, daily monitoring includes CBC with differential, hepatic panel, renal function, and urinalysis. During the taper, weekly then monthly monitoring continues with the same labs plus thyroid function tests. Thyroid function should be monitored for at least 12 months after DRESS resolution, as hypothyroidism is the most common delayed autoimmune sequela. Cardiac monitoring with echocardiogram is warranted for any cardiac symptoms, as myocarditis can present weeks after skin resolution. HHV-6, CMV, and EBV PCR testing should be obtained if worsening occurs despite drug withdrawal or if the course is atypical.

<image>Flowchart for DRESS syndrome workup and management showing initial evaluation with labs and RegiSCAR scoring, acute management with drug withdrawal and systemic corticosteroids with slow taper schedule, and long-term monitoring timeline for thyroid function, cardiac screening, and herpesvirus reactivation over 12 months</image>

Long-Term Considerations

Cross-reactivity of 40 to 58% exists among aromatic anticonvulsants (phenytoin, carbamazepine, phenobarbital), and all structurally related drugs should be avoided. Family screening is important because first-degree relatives of patients with aromatic anticonvulsant DRESS have a 25% risk due to shared slow acetylator phenotype. HLA testing before drug initiation is recommended for specific populations: HLA-B58:01 before allopurinol in Southeast Asian and African American patients, HLA-A31:01 before carbamazepine in European and Japanese patients, and HLA-B*57:01 before abacavir (standard of care). The culprit drug and the nature of the reaction (DRESS, not simple allergy) should be clearly documented in the medical record.

Key Clinical Pearls

Facial edema is the clinical feature most suggestive of DRESS and distinguishes it from simple morbilliform eruption. DRESS has a 2 to 8 week latency, much longer than morbilliform eruptions (5 to 14 days) or SJS/TEN (4 to 28 days). Herpesvirus reactivation (especially HHV-6) is integral to DRESS pathogenesis and may drive organ damage. The corticosteroid taper must be prolonged (8 to 12 or more weeks) because rapid taper causes relapse in over 50% of cases. Thyroid function should be monitored for at least 12 months post-DRESS, as autoimmune thyroiditis is the most common delayed sequela.

References

1. Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction — results from the prospective RegiSCAR study. Br J Dermatol. 2013;169(5):1071-1080.
2. Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int. 2006;55(1):1-8.
3. Cho YT, Yang CW, Chu CY. Drug reaction with eosinophilia and systemic symptoms (DRESS): an interplay among drugs, viruses, and immune system. Int J Mol Sci. 2017;18(6):1243.
4. Phillips EJ, Chung WH, Garon SL, Pirmohamed M. Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol. 2018;141(2):S545-S558.

Read this lecture as Markdown